PMID- 29353332
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20190122
IS  - 1436-3305 (Electronic)
IS  - 1436-3291 (Linking)
VI  - 21
IP  - 5
DP  - 2018 Sep
TI  - First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients 
      with advanced gastric cancer: a multicenter propensity score matched study.
PG  - 792-801
LID - 10.1007/s10120-018-0797-y [doi]
AB  - BACKGROUND: Fluoropyrimidine and platinum combination is the standard treatment 
      for advanced or recurrent gastric cancer (AGC). However, fluoropyrimidine 
      monotherapy is commonly used for elderly patients with AGC because of its good 
      tolerability. METHODS: In this multicenter retrospective study, we collected 
      clinical data of AGC patients aged 70 years or older, treated with S-1 alone or 
      S-1 plus cisplatin (SP) as the first-line treatment between January 2009 and 
      December 2011. Propensity score matched cohorts (PSMC) were used for reducing the 
      confounding effects to compare efficacy and safety between the two treatment 
      groups. Cox regression analysis was performed to clarify the prognostic factors. 
      RESULTS: PSMC (n = 109 in each group) were selected from among 444 eligible 
      patients (S-1 group, 210; SP group, 234); the S-1 group included more patients 
      deemed unfit for intensive chemotherapy than the SP group (e.g., higher age, 
      poorer PS, poor renal function). In the PSMC, patients' characteristics were 
      comparable between groups, except the male ratio (S-1 group, 64.2%; SP group, 
      77.1%; p = 0.04). No significant differences were observed in either overall 
      survival [hazard ratio (HR) 0.93, p = 0.63] or progression-free survival (HR 
      1.09, p = 0.61). Severe adverse events (AEs) and hospitalization due to AEs were 
      more frequent in the SP group than in the S-1 group (p < 0.001 each). CONCLUSION: 
      Our findings do not support the survival benefit of SP over S-1 in elderly 
      patients with AGC. We are now conducting a prospective comparative study to 
      optimize treatment strategy and explore applicability of the geriatric assessment 
      for these patients.
FAU - Makiyama, Akitaka
AU  - Makiyama A
AD  - Department of Hematology/Oncology, Japan Community Healthcare Organization, 
      Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, 806-8501, Japan. 
      makiyama20@hotmail.com.
FAU - Kunieda, Kenji
AU  - Kunieda K
AD  - Department of GI Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
FAU - Noguchi, Masaaki
AU  - Noguchi M
AD  - Department of Gastrointestinal Oncology, National Cancer Center Hospital East, 
      Kashiwa, Japan.
FAU - Kajiwara, Takeshi
AU  - Kajiwara T
AD  - Department of Gastrointestinal Medical Oncology, National Hospital Organization 
      Shikoku Cancer Center, Matsuyama, Japan.
FAU - Tamura, Takao
AU  - Tamura T
AD  - Department of Medical Oncology, Kindai University Faculty of Medicine, 
      Osaka-Sayama, Japan.
FAU - Takeda, Koji
AU  - Takeda K
AD  - Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
FAU - Sugiyama, Junko
AU  - Sugiyama J
AD  - Department of Medical Oncology, Tonan Hospital, Sapporo, Japan.
FAU - Minashi, Keiko
AU  - Minashi K
AD  - Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
FAU - Moriwaki, Toshikazu
AU  - Moriwaki T
AD  - Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Sugimoto, Naotoshi
AU  - Sugimoto N
AD  - Department of Medical Oncology, Osaka International Cancer Institute, Osaka, 
      Japan.
FAU - Nagase, Michitaka
AU  - Nagase M
AD  - Department of Clinical Oncology, Nagoya Red-Cross Daiichi Hospital, Nagoya, 
      Japan.
FAU - Negoro, Yuji
AU  - Negoro Y
AD  - Division of Gastroenterological Medicine, Kochi Health Sciences Center, Kochi, 
      Japan.
FAU - Tsuda, Takashi
AU  - Tsuda T
AD  - Department of Clinical Oncology, St. Marianna University School of Medicine, 
      Kawasaki, Japan.
FAU - Shimodaira, Hideki
AU  - Shimodaira H
AD  - Department of Clinical Oncology, Tohoku University Hospital, Sendai, Japan.
FAU - Okano, Naohiro
AU  - Okano N
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan.
FAU - Tsuji, Akihito
AU  - Tsuji A
AD  - Department of Medical Oncology, Kagawa University Hospital, Kagawa, Japan.
FAU - Sakai, Daisuke
AU  - Sakai D
AD  - Department of Frontier Science for Cancer and Chemotherapy, Osaka University 
      Graduate School of Medicine, Osaka, Japan.
FAU - Yanagihara, Kazuhiro
AU  - Yanagihara K
AD  - Department of Medical Oncology, Kansai Electric Power Hospital, Osaka, Japan.
FAU - Ueda, Shinya
AU  - Ueda S
AD  - Department of Medical Oncology, Nara Hospital Kindai University School of 
      Medicine, Ikoma, Japan.
FAU - Tamura, Shingo
AU  - Tamura S
AD  - Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan.
FAU - Otsu, Satoshi
AU  - Otsu S
AD  - Department of Medical Oncology and Hematology, Oita University Faculty of 
      Medicine, Yufu, Japan.
FAU - Honda, Takuya
AU  - Honda T
AD  - Department of Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, 
      Japan.
FAU - Matsushita, Yuzo
AU  - Matsushita Y
AD  - Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan.
FAU - Okuno, Tatsuya
AU  - Okuno T
AD  - Division of Gastroenterology, Department of Internal Medicine Graduate School of 
      Medicine, Kobe University, Kobe, Japan.
FAU - Kashiwada, Tomomi
AU  - Kashiwada T
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
FAU - Nozaki, Akira
AU  - Nozaki A
AD  - Department of Clinical Oncology, National Hospital Organization Kyoto Medical 
      Center, Kyoto, Japan.
FAU - Ebi, Masahide
AU  - Ebi M
AD  - Department of Gastroenterology, Aichi Medical University School of Medicine, 
      Nagakute, Japan.
FAU - Okuda, Hiroyuki
AU  - Okuda H
AD  - Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan.
FAU - Shimokawa, Mototsugu
AU  - Shimokawa M
AD  - Cancer Biostatistics Laboratory, Clinical Research Institute, National Hospital 
      Organization Kyushu Cancer Center, Fukuoka, Japan.
FAU - Hironaka, Shuichi
AU  - Hironaka S
AD  - Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
FAU - Hyodo, Ichinosuke
AU  - Hyodo I
AD  - Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Baba, Eishi
AU  - Baba E
AD  - Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Boku, Narikazu
AU  - Boku N
AD  - Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 
      Tokyo, Japan.
FAU - Muro, Kei
AU  - Muro K
AD  - Department of Clinical Oncology and Outpatient Treatment Center, Aichi Cancer 
      Center Hospital, Nagoya, Japan.
FAU - Esaki, Taito
AU  - Esaki T
AD  - Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer 
      Center, Fukuoka, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180120
PL  - Japan
TA  - Gastric Cancer
JT  - Gastric cancer : official journal of the International Gastric Cancer Association 
      and the Japanese Gastric Cancer Association
JID - 100886238
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Cisplatin/administration & dosage
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Multivariate Analysis
MH  - Oxonic Acid/administration & dosage/therapeutic use
MH  - Propensity Score
MH  - Stomach Neoplasms/*drug therapy/*mortality/pathology
MH  - Tegafur/administration & dosage/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cisplatin
OT  - Elderly patients
OT  - Gastric cancer
OT  - Propensity score matching method (3-5 words)
OT  - S-1
EDAT- 2018/01/22 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/01/22 06:00
PHST- 2017/10/03 00:00 [received]
PHST- 2018/01/14 00:00 [accepted]
PHST- 2018/01/22 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/01/22 06:00 [entrez]
AID - 10.1007/s10120-018-0797-y [pii]
AID - 10.1007/s10120-018-0797-y [doi]
PST - ppublish
SO  - Gastric Cancer. 2018 Sep;21(5):792-801. doi: 10.1007/s10120-018-0797-y. Epub 2018 
      Jan 20.